NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SNY

Sanofi ADR

May 30 • 04:00PM ET

49.37

Dollar change -2.98
Percentage change -5.69	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: PVAL GCOW FVD PPH AVDE PID APIE QQQJ PINK BUSA

Scroll to Statements

Index	-	P/E	20.62	EPS (ttm)	2.39	Insider Own	0.02%	Shs Outstand	2.61B	Perf Week	-5.98%
Market Cap	120.29B	Forward P/E	9.88	EPS next Y	5.00	Insider Trans	0.00%	Shs Float	2.44B	Perf Month	-10.15%
Income	6.02B	PEG	1.59	EPS next Q	0.94	Inst Own	10.73%	Short Float	0.15%	Perf Quarter	-9.36%
Sales	44.44B	P/S	2.71	EPS this Y	23.18%	Inst Trans	-1.20%	Short Ratio	1.26	Perf Half Y	2.11%
Book/sh	32.01	P/B	1.54	EPS next Y	9.29%	ROA	4.29%	Short Interest	3.69M	Perf Year	2.98%
Cash/sh	3.21	P/C	15.37	EPS next 5Y	12.93%	ROE	7.34%	52W Range	45.80 - 60.12	Perf YTD	2.36%
Dividend Est.	2.33 (4.73%)	P/FCF	15.12	EPS past 5Y	13.05%	ROI	6.39%	52W High	-17.87%	Beta	0.51
Dividend TTM	2.21 (4.48%)	Quick Ratio	0.73	Sales past 5Y	2.13%	Gross Margin	63.49%	52W Low	7.79%	ATR (14)	1.26
Dividend Ex-Date	May 09, 2025	Current Ratio	1.08	EPS Y/Y TTM	2.96%	Oper. Margin	23.14%	RSI (14)	38.24	Volatility	3.13% 2.29%
Employees	84587	Debt/Eq	0.23	Sales Y/Y TTM	-4.57%	Profit Margin	13.54%	Recom	1.62	Target Price	66.39
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	-	Payout	66.96%	Rel Volume	1.60	Prev Close	52.35
Sales Surprise	3.35%	EPS Surprise	3.11%	Sales Q/Q	-	Earnings	Apr 24 BMO	Avg Volume	2.92M	Price	49.37
SMA20	-4.96%	SMA50	-6.31%	SMA200	-6.97%	Trades		Volume	4,669,947	Change	-5.69%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight

Show Previous Ratings

May-30-25 06:23PM	Analyst Report: Sanofi (Morningstar Research) -5.69%
04:23PM	Regeneron stock sinks over trial data for smoker's lungs drug (Yahoo Finance Video)
11:59AM	Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More (Investopedia)
10:31AM	COPD Drug Developed by Regeneron, Sanofi Fails Key Test (Investopedia)
10:19AM	Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies (Zacks)
10:11AM	Loading…
10:11AM	Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. (Barrons.com)
10:00AM	Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates (Zacks)
08:59AM	Regeneron Pharmaceuticals Crashes 18% On A Surprise Sanofi-Tied Failure (Investor's Business Daily)
08:30AM	Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data (Benzinga)
08:08AM	Stocks to Watch Friday: Dell, Costco, Ulta, Regeneron (The Wall Street Journal)
06:37AM	Regeneron shares slide on mixed trial data for smoker's lung drug (Reuters)
06:34AM	Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials (The Wall Street Journal)
04:25AM	Sanofi, Regeneron shares nosedive after mixed Itepekimab results (Investing.com)
03:19AM	Sanofi, Regenerons Itepekimab Delivers Mixed Results in Late-Stage Trials (The Wall Street Journal)
01:00AM	Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies (GlobeNewswire)
01:00AM	Loading…
01:00AM	Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials (GlobeNewswire)
May-29-25 08:30AM	Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs (GlobeNewswire)
03:46AM	Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle (PR Newswire)
May-27-25 11:19AM	TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock? (Zacks)
10:00AM	RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? (Zacks)
01:00AM	Press Release: Sanofi completes acquisition of DR-0201 (GlobeNewswire)
May-23-25 08:16AM	Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More (Zacks)
07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
06:19AM	FDA Approves GSK's Nucala for Expanded Use in COPD (Zacks)
May-22-25 07:50PM	Vigil Neuroscience to be acquired by Sanofi for $8.00 per share (TipRanks)
05:30PM	Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence (PR Newswire)
12:20PM	Sanofi buys Vigil Neuroscience for $470m in Alzheimers push (Pharmaceutical Technology)
11:40AM	Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi (Investopedia)
10:48AM	MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot (Zacks)
10:14AM	Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout (Zacks)
10:06AM	Loading…
10:06AM	Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying (Investor's Business Daily)
08:05AM	Sanofi gains experimental Alzheimers drug through Vigil buyout (BioPharma Dive)
07:21AM	Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition (Benzinga)
May-21-25 09:21PM	Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal (Insider Monkey)
08:22PM	Sanofi to acquire Vigil Neuroscience in Alzheimers drug play (Investing.com)
07:59PM	Sanofi to Buy Vigil Neuroscience for About $470 Million (The Wall Street Journal)
07:30PM	Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi (GlobeNewswire)
07:15PM	Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline (GlobeNewswire)
10:51AM	Viz.ai, Sanofi and Regeneron to link for COPD management (Pharmaceutical Technology)
May-20-25 12:12PM	ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care (Pharmaceutical Technology)
07:30AM	Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) (Business Wire)
May-19-25 03:42PM	Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine (GuruFocus.com)
12:30PM	Power of collaboration more pertinent than ever says pharma experts (Pharmaceutical Technology)
09:42AM	NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine (Zacks)
09:39AM	Novavax Stock Soars on FDA Approval for New COVID-19 Vaccine (Investopedia)
04:58AM	Judge shuts down drugmakers 340B rebate plans, for now (Healthcare Dive)
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-15-25 01:06PM	Sanofi: Information concerning the total number of voting rights and shares - April 2025 (GlobeNewswire)
12:55PM	French finance minister criticises Sanofi's $20 billion USA investment decision (Reuters)
09:44AM	Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock (Zacks)
07:47AM	Sanofi commits at least $20bn to US manufacturing through 2030 (Pharmaceutical Technology)
07:13AM	Sanofi to pour more than $20B into US drug research and manufacturing (BioPharma Dive)
May-14-25 12:42PM	France's Sanofi to invest at least $20 billion in US through 2030 (Reuters)
12:30PM	Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing (PR Newswire)
May-13-25 11:15AM	Sanofi (SNY): A Bull Case Theory (Insider Monkey)
May-12-25 04:58PM	Analyst Report: Sanofi (Morningstar Research)
07:38AM	Trumps Vow to Cut US Drug Prices Drags Pharma Stocks Lower (Bloomberg)
04:28AM	Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg)
May-09-25 10:23PM	Drug companies to pay Hawaii $700 million to settle Plavix blood thinner lawsuit (Associated Press Finance)
01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
May-08-25 01:31PM	COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why (Benzinga)
01:25PM	Sanofi exec tells biotechs not to scrimp on clinical trial design (Clinical Trials Arena)
May-07-25 01:11PM	Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended (Zacks)
01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-05-25 07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
03:04AM	European Firms Fare Better Than Feared Through Early Trade Pain (Bloomberg)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks)
12:00PM	Sanofi: Information concerning the total number of voting rights and shares - March 2025 (GlobeNewswire)
May-01-25 01:30PM	Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell (Seeking Alpha)
08:15AM	Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader (GuruFocus.com)
Apr-30-25 12:46PM	Press Release: Annual General Meeting of April 30, 2025 (GlobeNewswire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
11:30AM	The Davenport Balanced Fund Q1 2025 Commentary (Seeking Alpha)
10:30AM	The Davenport Value & Income Fund Q1 2025 Commentary (Seeking Alpha)
07:00AM	Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader (GlobeNewswire)
03:12AM	Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ... (GuruFocus.com)
Apr-29-25 01:22PM	Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down (Zacks)
09:12AM	AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs (Zacks)
08:27AM	Regeneron's first-quarter results miss on lower Eylea demand (Reuters)
07:00AM	Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race (GlobeNewswire)
Apr-28-25 08:16AM	Private Equity Firms Target Defense Assets Once Seen as Toxic (Bloomberg)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-25-25 06:34AM	Halozyme sues Merck; FDA blames cuts for Vanda delay (BioPharma Dive)
05:13AM	Analyst Report: Sanofi (Morningstar Research)
01:47AM	Swiss Agree to Tariff Negotiations With Trump Administration (Bloomberg)
12:01AM	Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program (PR Newswire)
Apr-24-25 04:13PM	Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed (Investor's Business Daily)
02:03PM	Sanofi (SNY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
12:40PM	Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail (Clinical Trials Arena)
10:03AM	French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit (Benzinga)
07:59AM	Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth (Zacks)
07:00AM	Sanofi stays on course amid tariff turmoil (BioPharma Dive)
04:48AM	Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug (The Wall Street Journal)
01:30AM	Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed (GlobeNewswire)
Apr-23-25 02:50PM	Why vaccine makers aren't worried about Trump administration cuts (Yahoo Finance)
12:37PM	Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More (Zacks)
09:25AM	The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi (Zacks)
02:44AM	European pharma companies push for higher drug prices in EU amid U.S. tariff threats (Reuters)
Apr-22-25 09:06AM	Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast? (Zacks)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience